The company has not filed an annual or quarterly report since its Q2 FY2020 10-Q, filed Jul 30, 2020. Its latest SEC filing is a SC 13G/A from Feb 16, 2021.
10-Q for Q2 FY2020, filed Jul 30, 2020
The sections below describe the company as of the FY2019 annual report.
Developed PALFORZIA, a peanut-allergy treatment for patients, and other food-allergy candidates, with sales efforts aimed at allergists.
10-K for FY2019, filed Feb 27, 2020We are a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. It is…View ↗
PALFORZIATM (Peanut (Arachis hypogaea) Allergen Powder-dnfp) (formerly AR101) is our lead internally developed product utilizing CODIT and…View ↗
We are developing additional CODIT product candidates beyond peanut allergy. In August 2019, we commenced a Phase 2 clinical trial in…View ↗
Sales and MarketingView ↗
No revenue was reported.
10-K for FY2019, filed Feb 27, 2020
Aimmune aimed to reach patients with moderate to severe food allergies, particularly children and adolescents, through a specialty sales force that called on practicing allergists.
10-K for FY2019, filed Feb 27, 2020Sales and MarketingView ↗
8-K, filed Oct 19, 2020
As described in the Introductory Note above, on October 13, 2020, Merger Sub irrevocably accepted for payment all Shares validly tendered…View ↗
From development to commercialization
The lead peanut-allergy product progressed from an investigational candidate to an FDA-approved treatment, and the company began commercializing it in the United States.
10-K for FY2016, filed Mar 15, 2017 10-K for FY2019, filed Feb 27, 2020Our lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy, which affects…View ↗
PALFORZIATM (Peanut (Arachis hypogaea) Allergen Powder-dnfp) (formerly AR101) is our lead internally developed product utilizing CODIT and…View ↗
Competes with DBV Technologies
10-K for FY2019, filed Feb 27, 2020Currently, other than PALFORZIA, there are no FDA-approved medical therapies for the treatment of food allergies. In October 2017, DBV…View ↗
Loading...
